Blog • Generis Group

Enhancing the Tech Transfer Process in the Pharmaceutical Sector with Maik Helmut Talarczyk, Director and Head, PMO and ESO at Sandoz [Speaker Spotlight]

Written by Devyn Smith | March 25, 2025 12:33:06 PM Z

The pharmaceutical industry is constantly evolving, and at the heart of these changes is the critical process of tech transfer. As we approach the European Pharma Outsourcing Summit, we had the opportunity to sit down with Maik Helmut Talarczyk, Director and Head of PMO and ESO at Sandoz, to gain insights into the strategies and trends shaping this important field.

Maik will join industry leaders from CSL Behring, UCB, Gilead Sciences, and Alexion Pharmaceuticals on stage to share his expertise on this crucial topic.

With over 22 years of experience in managing interdisciplinary and global projects, Maik shares his expertise in aligning business objectives with technical goals, driving innovation, and leading successful tech transfer processes.

 

 

Can you kindly introduce yourself and describe your role/responsibilities as the Director and Head, PMO and ESO at Sandoz and your journey into the pharmaceutical world?

 

My name is Maik Helmut Talarczyk, and I am the Director and Head of PMO and ESO at Sandoz. I am a seasoned director with over 22 years of experience managing interdisciplinary and global projects, leading improvement programs, and developing site strategies. I possess extensive expertise in Lean Six Sigma, site strategy development, engineering, technology and product development, risk and quality management, and establishing new supplier structures.

I am a proven leader in driving cultural change and organizational transformation, with numerous successes in building and transferring company locations and product lines. I combine deep technical and business knowledge with a hands-on mentality, ensuring effective execution and results. With a strong ability to adapt to diverse work environments and teams, a solid academic background, and exceptional leadership skills, I bring comprehensive experience across all stages of project management in cross-cultural and international settings.

 

 

 

What strategies ensure the alignment of business objectives with the technical and operational goals of tech transfer?

 

To ensure the alignment of business objectives with the technical and operational goals of a tech transfer in the pharmaceutical industry, a structured approach that integrates strategic, technical, and regulatory considerations is essential.

Key success factors include:

  • Cross-Functional Governance
  • Strategic Tech Transfer Plan
  • Risk-Based Approach
  • Data-Driven Decision Making
  • Regulatory and Quality Alignment
  • Knowledge Transfer & Training
  • Supply Chain & Manufacturing Readiness
  • Change Management & Communication

These elements collectively ensure a smooth and successful transition, minimizing risks and maximizing efficiency throughout the process.

 

 

 

What emerging trends are likely to reshape tech transfer practices in the coming years?

 

Digitalization and Industry 4.0 are increasingly shaping the future of pharmaceutical manufacturing and tech transfer. These technologies incorporate AI and machine learning, digital twins, and cloud-based data sharing to enhance efficiency and decision-making.

Advanced process analytical technology and real-time monitoring enable greater process control and optimization, allowing for more precise and consistent outcomes.

Additionally, standardization and modularization streamline operations, making processes more adaptable and scalable. Data-driven knowledge management ensures effective information flow, facilitating informed decision-making and continuous improvement.

Harmonized regulatory frameworks play a crucial role in facilitating global transfers with fewer compliance hurdles, reducing complexity and accelerating implementation.

The shift toward decentralized and continuous manufacturing enhances flexibility and scalability, allowing for more efficient production models.

Finally, regulatory harmonization and digital submissions support seamless global compliance, improving the efficiency of regulatory approvals and ensuring smoother market access.

 

 

How might the rise of personalized medicine and smaller batch sizes impact the tech transfer process? 

 

Traditional large-scale process validation methods, such as three-batch validation, may not be feasible for personalized therapies due to their unique and patient-specific nature.

As a result, adaptive validation approaches, including real-time monitoring and continuous verification, become essential to ensure process reliability and compliance while accommodating the smaller-scale, highly customized nature of these treatments.

Additionally, more stringent cold chain and logistics considerations are necessary to maintain product integrity, as personalized therapies often involve highly sensitive biological materials that require precise temperature control and secure transportation.

 

 

"Creativity, in this context—this might seem like an abstract analogy—is like arranging rocks. You have a set of rocks in front of you, and you can line them up in a row, stack them in a pile, place them horizontally, vertically, or even shape them into a triangle. The way you arrange them changes the perception of what they are. That's what I mean by creativity—it's about how you organize and approach things to create a meaningful outcome."

 

 

 

 

 

Which aspect of the European Pharma Outsourcing Summit are you most looking forward to?

 

I'm looking forward to learning and networking at the European Pharma Outsourcing Summit. The sessions that I'm most excited for are:

  • Leveraging CDMO Partnerships for Strategic Advantage
  • Ensuring Excellence: Effective Supplier Management in Pharma Outsourcing
  • Enhancing Contract Manufacturing Operations for Optimal Results
  • Optimizing Pharma Outsourcing: Strategies for Effective External Partnerships
  • Strategies for Commercial Management: Leveraging Branding and CDMO Expertise

 

 

We thank Maik for taking the time to share his invaluable insights, and we look forward to his session, "Enhancing the Tech Transfer Process in the Pharmaceutical Sector," at the European Pharma Outsourcing Summit taking place on 5-6 June 2025 in Düsseldorf, Germany. Join us to hear Maik’s perspectives, and don’t miss the chance to engage with him and 35+ other speakers live at the summit!